Background: Levitra, a phosphodiesterase-5 (PDE5) inhibitor, is the trade name of vardenafil. Nowadays, it is applied to treatment of erectile dysfunction. PDE5 inhibitors are employed to induce dilatation of the vascular smooth muscle. The effect of Levitra on impotency is well known; however, its effect on the tracheal smooth muscle has rarely been explored. When administered for sexual symptoms via oral intake or inhalation, Levitra might affect the trachea. Methods: This study assessed the effects of Levitra on isolated rat tracheal smooth muscle by examining its effect on resting tension of tracheal smooth muscle, contraction caused by 10 À6 M methacholine as a parasympathetic mimetic, and electrically induced tracheal smooth muscle contractions.
Introduction
The enzyme phosphodiesterase-5 (PDE5) is known to be abundant in lung tissue where it hydrolyses cyclic guanosine monophosphate (cGMP), a second messenger of NO, causing constriction of the blood vessel walls. 1 Four PDE5 inhibitors namely sildenafil, tadalafil, vardenafil and avanafil have been clinically approved for treating erectile dysfunction (ED). 2 They are also employed to induce dilatation of the vascular smooth muscle and to inhibit platelet aggregation in treating testicular torsion, pulmonary hypertension, coronary artery disease, diabetes mellitus, chronic peripheral arterial diseases, ischemic colitis and acute mountain sickness. 3e9 There should be particular caution when prescribing PDE5 inhibitors for erectile dysfunction in patients receiving protease inhibitors. PDE5 inhibitors appear to work in men regardless of the reasons behind their erectile dysfunction, including vascular disease, nerve problems, and even psychological causes. PDE5-inhibiting drugs can have a number of side effects, including headache, dizziness, Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.
lightheadedness, flushing, nasal congestion, and changes in vision.
10 (see Figs. 1e5) Levitra is the trade name of vardenafil. It has been used as a PDE5 inhibitor to treat ED for a decade. 2 The side effects of PDE5 inhibitors had been reported but their effect on the trachea was rarely mentioned. During an asthma attack, the tracheal smooth muscle becomes contracted, thus reducing pulmonary function. A male patient with asthma may also apply this drug via oral intake or inhalation for his sexual problems. Hence, the effect of Levitra on tracheal smooth muscle merits further exploration. The aim of this study was to determine the effects of Levitra on the isolated tracheal smooth muscle in vitro.
Methods
Chemicals used were of the highest purity available. Levitra was obtained courtesy of Bayer Co., Taiwan. All other chemical reagents were obtained from Sigma (St. Louis, MO, USA). Methacholine was tested as a tracheal contraction drug. After being anesthetized by intraperitoneal administration of pentobarbital (45 mg/kg), 18 male SpragueeDawley rats (weighing 250e300 g) were humanely killed by cervical dislocation, and two pieces of trachea (~5 mm in length) were removed from each rat. This study was approved by an animal experiment review board (IACUC-07-133). The tracheal specimen was mounted using two steel plates and submersed in a 30-mL muscle bath at 37 C as previously reported. 11, 12 Briefly, the bath was filled with 30 mL Krebs solution consisting of (mmol/L): NaCl, 118; KCl, 4. The peak tension of the tracheal strip evoked by EFS during the addition of 10 À4 M Levitra was significantly lower than that at the addition of 10 À8 M Levitra (p < 0.001). Results were mean ± SD (n ¼ 6).
tracheal strip was attached to a Grass FT-03 force displacement transducer (AstroMed, West Warwick, RI, USA) using a steel plate and a 3-0 silk ligature. The other side of the strip was fixed to a steel plate attached to the bath. A passive tension of 0.3 g was applied to the strips and subsequent changes in tension were continuously recorded using Chart V 4.2 software (PowerLab, AD Instruments, Colorado Springs, CO, USA). Preliminary tests showed that the tracheal strip immersed in the bath solution used for subsequent experiments did not contract when basal tension was applied. Prior to drug assays, isolated tracheas were equilibrated in the bath solution for 15e30 min, during which they were continuously aerated with a mixture of 95% O 2 and 5% CO 2. Stepwise increases in the amount of drugs used were made to study the contraction or relaxation responses of the tracheal strips. All drugs were administered by adding a defined volume of stock solution to the tissue bath solution. In each experiment, one untreated strip served as a control. Electrical field stimulation (EFS) (5-Hz, 5-ms pulse duration, at 50 V, trains of stimulation for 5 s) was applied to the trachea strip with two wire electrodes placed parallel to the trachea strip and connected to a direct-current stimulator (Grass S44, Quincy, MA, USA). An interval of 2 min was imposed between each stimulation period to allow recovery from the response. Stimulation was continuously applied to the trachea at 37 C. The following assessments for Levitra were made. (1) Effect on tracheal smooth muscle resting tension: this test examined the effect of the drug on the simulating condition of resting trachea condition. (2) Effect on contraction caused by 10 À6 M methacholine (a parasympathetic mimetic): this procedure examined postsynaptic events such as muscle-receptor blockade, enhancement, and second messengers. (3) Effect of Levitra on electrically induced contractions: electrical stimulation of this tissue causes parasympathetic nerve remnants in the trachea to release a transmitter (acetylcholine). If there is interference with transmitter release, electrical stimulation does not cause contraction. Thus, presynaptic events were seen more easily with this procedure.
The concentrations of drugs were expressed as concentrations present in the 30-mL bath solution. Data were presented as Mean ± SD and statistical significance was tested using a two-tailed Student's t-test; p values less than 0.05 were considered significant.
Results
The tension applied to the transducer could indicate the degree of contraction or relaxation of the tracheal strips. Tracheal contraction induced by a small dose of methacholine was easily detected, and the tissue remained in a contracted state until the drug was rinsed from the tissue.
Addition of Levitra to the basal tension elicited a negligible effect (Fig. 1) . When introduced after adding a constricting agent such as 10 À6 M methacholine, Levitra resulted in relaxation of the trachea (Fig. 2) . Low doses of Levitra mildly affected contraction while higher doses significantly relaxed the trachea smooth muscle (Figs. 2, 3 ). With 10 À8 M Levitra added, the tension was 98.2 ± 2.6% of the control values (Fig.  3) . At the addition of 10 À5 M and 10 À4 M Levitra, the tensions were 29.3 ± 12.8% and 11.2 ± 4.2%, respectively (Fig. 3) . The differences in tension among the specimens treated with 10 À8 M Levitra and 10 À5 M or 10 À4 M Levitra were statistically significant (p < 0.05).
Levitra also inhibited the spike contraction induced by EFS (Figs. 4, 5) . The spike contraction was decreased with increase in Levitra concentration. The minimal increasing basal tone was not significant. The peak tension of the tracheal strip evoked by EFS with 10 À8 M Levitra added was 100 ± 0%; whereas at the addition of 10 À5 M and 10 À4 M Levitra, the peaks were 41.2 ± 16.4% and 0, respectively (Fig. 5) . The peak tension of the tracheal strip evoked by EFS with 10 À5 M or 10 À4 M Levitra added was significantly lower than that at the addition of 10 À8 M Levitra (p < 0.05).
Discussion
PDE5 was identified as the enzyme that degraded cGMP.
1
PDE5 resides in vascular smooth muscle cells and platelets.
Researchers theorized that inhibition of this enzyme offered potential benefits for patients with hypertension or angina. The initial study designed to assess the safety of PDE5 inhibitors revealed no unusual findings. In 1992, a multiple-dose phase 1 trial was initiated. A few of the study patients reported an adverse event with a tendency to get erections. The drug was tested in men with angina laterally. The hemodynamic effects were fairly mild. Rajfer et al. reported that nitric oxide (NO) caused smooth muscle relaxation in human cavernous tissue. 13 The basic mechanism involved sexual stimulation that triggered the release of NO from nerve endings in the penis. The NO in turn stimulated the production of cGMP, which dilated penile blood vessels and relaxed the smooth muscle in the walls of the cavernous sinusoids. The effects promote engorgement of the penis and penile rigidity. 14 An earlier report reviewed the effects of PDE1-5 inhibitors on airway smooth muscle in vitro and in vivo. 15 Isoenzyme-selective PDE inhibitors, especially PDE 4, might be useful airway smooth muscle relaxants in the treatment of lung disorders. Reports regarding the effects of PDE5 inhibitors on tracheal smooth muscle were scarce. This study showed that a PDE5 inhibitor such as Levitra did have effects on trachea smooth muscles.
This study was effective and simple. An intact tracheal ring, which is much more representative of a physiological setting than smooth muscle strips, was an important component of the technique involved. 11, 12 It was difficult to determine which tissue component of the trachea was responsible for the druginduced contraction, but the nature of the specific tissues and their responses to specific drugs provided some indication. The present results could be interpreted within the context of the test materials used. The tracheal strips used in this study were crude preparations containing tracheal smooth muscle and cartilage. The smooth muscle of the trachea appeared to be the main tissue component responsible for contraction. Other components such as epithelium, glands, connective tissue, nerves, and cartilage did not contract to a significant extent. Since this method involved cross contraction, changes in tension were caused by radial contraction of the tracheal ring. Responses to drugs and electrical stimulation have been verified for similar preparations, 16e18 but the contractile response observed in this study was probably an aggregate of the responses of various types of muscle tissue. It was not easy to obtain human tissue for similar studies. The effect of this drug on isolated human tracheal smooth muscle still needs further investigation. Since this was an in vitro study, there were reservations as to its comparability with an in vivo situation in humans. In the in vivo situation, the response might be much more complicated than that in the in vitro situation.
By increasing microcirculatory blood flow, PDE5 inhibitors positively affect the oxygen uptake of tissue and are thus employed to treat patients with chronic peripheral arterial diseases and acute mountain sickness. 19 In view of the above results, Levitra might be an effective treatment option in asthmatic patients. The adverse event profiles of PDE5 inhibitors are generally similar. Class-specific side effects include headache, flushing, nasal congestion, dyspepsia and myalgia, which reflect the vasodilatory effects on the capillary smooth muscle in other parts of the body. In this study, Levitra alone had minimal effect on the basal tension of trachea as the concentration increased.
The cholinergic contracting agent tested in this preparation is commonly used for research purposes. Of note is that Levitra-induced relaxation of tissue depends on prior partial contraction of the smooth muscle after applying methacholine. Thus, it should be possible to assess the effects of common drugs and potential therapeutic agents supposedly responsible for relieving asthma attacks. Levitra, a PDE5 inhibitor, could reduce methacholine-induced contraction. Commercial oral Levitra dosage is 10 or 20 mg. The blood concentration would reach 10 À5 M one hour after oral intake. It would undoubtedly affect the trachea. The mechanism by which Levitra affected the trachea smooth muscle is unknown and further studies are needed to elucidate the answer.
Electrical field stimulation is a common experimental tool; it activates the nerve terminals within the tissue to be tested and induces release of endogenous neurotransmitters, thereby triggering smooth muscle contraction. EFS-induced spike contraction of canine nasal mucosa, which is believed to result from the contraction of vascular smooth muscles, disappeared following ipsilateral cervical sympathetic ganglionectomy. 20 Thus, EFS-induced spike contraction of isolated canine nasal mucosa was proven to be mediated by sympathetic innervations. 20 In this study, EFS-induced spike contraction of the tracheal smooth muscle was attributed to stimulation of parasympathetic innervation. Therefore, EFS-induced contraction of the trachea decreased as the Levitra concentration increased. These findings suggested that Levitra could antagonize the parasympathetic innervation responsible for trachea smooth muscle contraction. If there is interference with transmitter release, electrical stimulation does not cause contraction. The inhibition of parasympathetic acetylcholine release by Levitra in this case was plausible. In addition, basal tension elicited minimal effect with various concentrations of Levitra. Clearly, what was observed in this study is very interesting, but further study is needed to clarify these phenomena.
The results of the present study showed that high concentrations of Levitra might actually inhibit parasympathetic function of the trachea. It could also reduce methacholineinduced contraction. In addition to ED symptoms, Levitra could effectively treat an asthmatic attack. In an in vivo situation, the response might be much more complicated than that in an in vitro situation.
In conclusion, vardenafil could reduce methacholineinduced contraction of the tracheal smooth muscle. High concentrations of vardenafil might actually inhibit parasympathetic function of the trachea. Vardenafil might reduce asthmatic attacks when administered to ED patients.
